BR100 Increased By (0.07%)
BR30 Increased By (0.52%)
KSE100 Increased By (0.26%)
KSE30 Increased By (0.34%)
AGHA 6.45 Increased By ▲ 0.13 (2.06%)
BECO 4.36 Increased By ▲ 0.09 (2.11%)
BML 62.18 Decreased By ▼ -0.27 (-0.43%)
BOP 31.43 Increased By ▲ 0.20 (0.64%)
CNERGY 11.73 Increased By ▲ 0.14 (1.21%)
CSIL 5.89 Increased By ▲ 0.17 (2.97%)
FCCL 60.70 Decreased By ▼ -0.84 (-1.36%)
FFL 14.72 Decreased By ▼ -0.30 (-2%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.32 Increased By ▲ 0.06 (0.96%)
KOSM 5.95 Increased By ▲ 0.39 (7.01%)
LOTCHEM 24.71 Increased By ▲ 0.03 (0.12%)
MLCF 103.00 Decreased By ▼ -1.08 (-1.04%)
NBP 172.98 Decreased By ▼ -2.30 (-1.31%)
NCPL 52.60 Decreased By ▼ -0.17 (-0.32%)
NPL 54.09 Decreased By ▼ -0.03 (-0.06%)
OGDC 316.99 Increased By ▲ 3.60 (1.15%)
PACE 9.28 Increased By ▲ 0.08 (0.87%)
PAEL 35.69 Decreased By ▼ -0.11 (-0.31%)
PIBTL 13.74 Increased By ▲ 0.27 (2%)
PPL 227.00 Increased By ▲ 5.19 (2.34%)
PRL 80.08 Increased By ▲ 1.00 (1.26%)
PTC 46.81 Decreased By ▼ -0.04 (-0.09%)
SSGC 23.96 Increased By ▲ 0.09 (0.38%)
TBL 9.27 Decreased By ▼ -0.04 (-0.43%)
TELE 7.57 Increased By ▲ 0.18 (2.44%)
TPL 24.66 Decreased By ▼ -0.45 (-1.79%)
TPLP 12.85 Increased By ▲ 0.34 (2.72%)
TREET 25.99 Decreased By ▼ -0.26 (-0.99%)
TRG 53.16 Decreased By ▼ -0.28 (-0.52%)
World

India's COVID-19 vaccination drive hits bump due to app glitch

  • India was aiming to vaccinate more than 300,000 people on Saturday, but only 191,181 people were inoculated on the first day.
Published Updated
By

SATARA/BHUBANESWAR: India's COVID-19 vaccination drive was still facing some delays on Sunday after it hit a bump on the first day due to glitches in an app used to coordinate the campaign, according to officials in some states.

Prime Minister Narendra Modi launched on Saturday what his government has described as the "world's largest vaccination programme". It aims to vaccinate around 300 million people to curb the pandemic in India, which has reported the second highest number of coronavirus cases after the United States.

India was aiming to vaccinate more than 300,000 people on Saturday, but only 191,181 people were inoculated on the first day, official data shows.

Many health workers, who were due to receive a vaccine on Saturday, did not get the message via an app developed by the government called Co-Win, officials in at least four states said. Officials in at least one state said the issues had still not been resolved on Sunday.

Co-Win is supposed to alert healthcare workers, who are first in line to get shots. It also allows officials to monitor and manage the entire programme.

"We were planning to vaccinate 28,500 people on Saturday but could do only 18,328 because of glitches in the Co-Win app," a senior official at the health department of the western state of Maharashtra told Reuters on condition on anonymity.

Maharashtra, home to the financial hub of Mumbai, has been the Indian state hit hardest by COVID-19.

In the eastern states of Odisha and West Bengal, officials said they were forced to use printouts on Saturday due to issues with the app.

"We also went with our plan B and contacted people to be vaccinated directly offline," Bijay Kumar Mohapatra, director, Health Services, Odisha, told Reuters in the state capital Bhubaneswar.

The Indian government did not respond to a request for comment on Sunday.

"The system performance and speed was improved and is being further optimised," Manohar Agnani, a senior health ministry official, said on Saturday.

The eastern state of West Bengal was still encountering glitches on Sunday.

"The problem is yet to be fixed and we are facing serious impediments," said Dr. Ajoy Chakraborty, director of West Bengal health services.

Officials in other states could not be reached for comment on Sunday.

India is currently using Britain's Oxford University/AstraZeneca vaccine, which is also being produced in India, and a government-backed vaccine developed by India's Bharat Biotech.

However, approval of Bharat Biotech's COVAXIN has been criticised by health experts and opposition lawmakers due to a lack of efficacy data, which the manufacturer is still conducting.

Comments

Comments are closed for this article.